Panasian system for coordination of efforts aiming the translational medicine development. Role and place of the In Silico models

A brief-n-clear synopsis of major trends in infrastructure development along with the expert groups activities within Shanghai Cooperation Organization (SCO), 2020–2025, has been presented and discussed following by an accent on both support and control over the national public health programs and, respectively, the translational medicine related innovation projects. An additional emphasize is made on attention expressed by the SCO expert community towards the arsenal of the In Silico mathematical models taking into account their role as the tools sustainable for optimization of the new drugs preclinical trial algorithms. Thus, announced for 2025–2030 ongoing SCO reform promotes an essential possibilities spread-out for its community of experts as this deals with both financial support and scientific expertise performance in case of the international research projects proposed by scientists from member-countries working in such areas as pharmacology/pharmacy and healthcare administration. Taking this into account, a scheme of interactions between the SCO Committees, Commissions and Expert Councils is under discussion, while a special attention to juridical and financial aspects was paid. As per peculiarities of planning and conduction of these SCO activities, this issue was studied within a context of comparison to analogical potential revealing in preclinical and clinical trials on new medicines carried out according to ACS (American Chemical Society) adopted protocols. Giving an example of achievements and perspectives of the SCO criteria fitting innovation projects: the results of preclinical studies (experimental and In Silico tracks) on PMC16-nanocationites designed for tumor cells targeting with a following release of paramagnetic isotopes ( 25 Mg, 43 Ca, 67 Zn) which promotes the corresponding magnetic isotope effects (MIE) and, hence, the MIE-induced cytostatic (anti-tumor) consequences. In conclusion, a data supported prove makes a lot of sense in attentive studies on both SCO experience and the current trends of its applications to pharmacological research including the use of the SCO-developed programs in mathematical modeling in medicine and, in particular, in upgrade of In Silico models.